Literature DB >> 11278156

Cannabis use is associated with schizotypy and attentional disinhibition.

P D Skosnik1, L Spatz-Glenn, S Park.   

Abstract

While most neurochemical research into the pathogenesis of schizophrenia (SZ) has focused on the dopaminergic, glutamatergic, and serotonergic systems, the exact nature and cause of this disorder have proven intractable. Given the recent discovery and elucidation of the endogenous cannabinioid system, a re-examination of the cannabis-induced exacerbation hypothesis of SZ is warranted. The purpose of the present study was to assess whether current cannabis users exhibit personality correlates and neurocognitive deficits similar to those observed in SZ patients. 15 current cannabis users, 15 drug-free controls, and 10 past cannabis users were assessed on tasks which assess attentional inhibition, spatial working memory, olfactory identification, and schizotypal personality. Current cannabis users demonstrated deficits in attentional inhibition, decreased reaction time, and significantly higher scores on the schizotypal personality questionnaire (SPQ) compared with the non-using and past cannabis using groups. No group differences were found on the working memory or olfactory identification tasks. These results suggest that cannabis use can mimic attentional deficits seen in acute schizophrenia and is associated with schizotypal personality, thus setting the stage for a possible cannabinoid model of SZ.

Entities:  

Mesh:

Year:  2001        PMID: 11278156     DOI: 10.1016/s0920-9964(00)00132-8

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  35 in total

Review 1.  Cannabis and psychosis.

Authors:  Louisa Degenhardt; Wayne Hall
Journal:  Curr Psychiatry Rep       Date:  2002-06       Impact factor: 5.285

2.  Neuropsychological effects associated with recreational cocaine use.

Authors:  Kirstie Soar; Colette Mason; Anita Potton; Lynne Dawkins
Journal:  Psychopharmacology (Berl)       Date:  2012-02-29       Impact factor: 4.530

3.  Association of abnormal semantic processing with delusion-like ideation in frequent cannabis users: an electrophysiological study.

Authors:  Michael Kiang; Bruce K Christensen; David L Streiner; Carolyn Roy; Iulia Patriciu; Robert B Zipursky
Journal:  Psychopharmacology (Berl)       Date:  2012-07-11       Impact factor: 4.530

4.  Association between cannabis use, psychosis, and schizotypal personality disorder: findings from the National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Glen P Davis; Michael T Compton; Shuai Wang; Frances R Levin; Carlos Blanco
Journal:  Schizophr Res       Date:  2013-11-05       Impact factor: 4.939

5.  Alterations to pre-pulse inhibition (PPI) in chronic cannabis users are secondary to sustained attention deficits.

Authors:  Kirsty Elizabeth Scholes; Mathew Thomas Martin-Iverson
Journal:  Psychopharmacology (Berl)       Date:  2009-10-09       Impact factor: 4.530

6.  Chronic cannabinoid exposure reduces phencyclidine-induced schizophrenia-like positive symptoms in adult rats.

Authors:  Maria Sabrina Spano; Liana Fattore; Francesca Cadeddu; Walter Fratta; Paola Fadda
Journal:  Psychopharmacology (Berl)       Date:  2012-08-19       Impact factor: 4.530

7.  Additive Effects of Former Methylenedioxymethamphetamine and Cannabis Use on Subclinical Psychotic Symptoms.

Authors:  Berker Duman; Nilay Sedes; Bora Baskak
Journal:  Noro Psikiyatr Ars       Date:  2017-03-01       Impact factor: 1.339

8.  Cannabis use and the risk of developing a psychotic disorder.

Authors:  Wayne Hall; Louisa Degenhardt
Journal:  World Psychiatry       Date:  2008       Impact factor: 49.548

9.  Neural correlates of performance monitoring in chronic cannabis users and cannabis-naive controls.

Authors:  Daniel J Fridberg; Patrick D Skosnik; William P Hetrick; Brian F O'Donnell
Journal:  J Psychopharmacol       Date:  2013-02-20       Impact factor: 4.153

Review 10.  Cannabis and psychosis/schizophrenia: human studies.

Authors:  Deepak Cyril D'Souza; Richard Andrew Sewell; Mohini Ranganathan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-16       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.